A Phase 3 interventional study of Placebo and Eptinezumab in Migraine, sponsored by H. Lundbeck A/S. Completed at 87 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.
Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 2nd largest by enrollment, is one of 5 that started in 2021, is one of 13 in phase 3, and was the 11th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–65
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 12–17
Dr George Medvedev · Sites in Canada
Ages 19–75
By country, each count listing its studies:
eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 981 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 193 across the 21 interventional studies. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 21 have an industry lead sponsor. The 5 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
23 studies in Migraine Disorders by H. Lundbeck A/S: 3 open now, 3 under way, 3 of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 23 studies in Migraine Disorders by H. Lundbeck A/S, this one is the 2nd largest by enrollment, is one of 6 that started in 2021, is one of 11 in phase 3, and was the 12th registered.
H. Lundbeck A/S’s Migraine Disorders studies by the year they started, since 2012.
3 of the studies testing eptinezumab in Migraine Disorders that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04965675Phase 3H. Lundbeck A/SA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | 2027-03-26 |
| NCT07191145Phase 3Sunnybrook Health Sciences CentreEary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) | 2027-06-30 |
| NCT05897320Phase 3H. Lundbeck A/SA Study of Eptinezumab in Pediatric Participants With Episodic Migraine | 2027-07-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies testing eptinezumab in Migraine Disorders, from their registry updates:
Among H. Lundbeck A/S’s 23 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
This study evaluates the efficacy of eptinezumab to prevent migraine in participants with chronic migraine.
This is an interventional, multi-regional, multi-site, randomized, double-blind, placebo-controlled Phase III study, to confirm the efficacy and safety of eptinezumab in participants with chronic migraine who are eligible for preventive treatment.
participants will be randomly allocated to one of three treatment groups: eptinezumab 300 mg, eptinezumab 100 mg, or placebo.
The double-blind, placebo-controlled treatment period will be followed by an extension period where all participants will receive active treatment to further assess the safety and tolerability of eptinezumab.
The total study duration from the Screening Visit to the Safety Follow-up Visit is approximately 36 weeks and includes a Screening Period (28-30 days), a Placebo-controlled Period (12 weeks), an Extension Period (12 weeks), and a Safety Follow-up Period (8 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion and exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
300 mg eptinezumab by intravenous (IV) infusion.
Drug: Eptinezumab
100 mg eptinezumab by IV infusion.
Drug: Eptinezumab
Placebo by IV infusion.
Drug: Placebo · Drug: Eptinezumab
0.9% normal saline, intravenously
Solution for infusion, intravenously
Also known as: Lu AG09221
Change from baseline in the number of monthly migraine days (MMDs) (Weeks 1-12)
Time frame: Weeks 1-12
Response: ≥50% reduction from baseline in MMDs (Weeks 1-12)
Time frame: Weeks 1-12
Response: ≥75% reduction from baseline in MMDs (Weeks 1-4)
Time frame: Weeks 1-4
Response: ≥75% reduction from baseline in MMDs, (Weeks 1-12)
Time frame: Weeks 1-12
Migraine rate on the day after dosing
Time frame: Day 1
Response: ≥50% reduction from baseline in monthly headache days (MHDs) (Weeks 1-12)
Time frame: Weeks 1-12
Change from baseline in the number of MHDs (Weeks 1-12)
Time frame: Weeks 1-12
Response: ≥75% reduction from baseline in MHDs (Weeks 1-4)
Time frame: Weeks 1-4
Change from baseline in rate of migraines with severe pain intensity (Weeks 1-12)
Time frame: Weeks 1-12
Change from baseline in rate of headaches with severe pain intensity (Weeks 1-12)
Time frame: Weeks 1-12
Change from baseline in the number of MMDs with use of acute medication (Weeks 1-12)
Time frame: Weeks 1-12
Patient Global Impression of Change (PGIC) score at week 12
Time frame: Week 12
Most Bothersome Symptom (MBS) score at Week 12, as measured relative to Screening
Time frame: Screening to Week 12
Change from baseline to Week 12 in the Headache Impact Test (HIT-6) score
Time frame: Baseline to Week 12
Change from baseline to Week 12 in the Migraine-Specific Quality of Life (MSQ v2.1) sub-scores (Role Function-Restrictive, Role Function-Preventive, Emotional Function)
Time frame: Baseline to Week 12
Change from baseline to Week 12 in the Health-Related Quality of Life (EQ-5D-5L) Visual Analogue Scale (VAS) score
Time frame: Baseline to Week 12
Health Care Resources Utilization (HCRU)
Migraine-specific healthcare resource utilization information will be collected in terms of outpatient health care professional visits, emergency room visits, hospital admissions, as well as duration of hospital stays.
Time frame: Baseline to Week 12
Change from baseline to Week 12 in the Work Productivity and Activity Impairment Questionnaire: Migraine (WPAI:M) sub-scores (Absenteeism, Presenteeism, Work productivity loss, Activity impairment)
Time frame: Baseline to Week 12
Ran from May 2021 to primary completion in Oct 2024, 40 months.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 40 months is above that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eptinezumab